CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 194 enrolled / 194 target
Drug / intervention
Teclistamabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04557098
NCT04557098Phase 2ActiveUpdate Overdue (2.8/mo)Completion was 55mo ago
CompareCT.gov

A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Teclistamab, a Humanized BCMA x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma

Janssen Research & Development, LLC·interventional·Posted Sep 21, 2020·Updated Jun 8, 2026

In Brief

A Phase 2 clinical trial evaluating Teclistamab for Hematological Malignancies. Active but no longer recruiting, targeting 194 participants across 51 sites in 11 countries.

Signals

Enrollment appears stalled

Detailed Summary

The purpose of this study is to evaluate the efficacy of teclistamab at the recommended Phase 2 dose (RP2D).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHematological Malignancies
CountriesBelgium, Canada, China, France, Germany, Italy, Netherlands, Spain, Sweden, United Kingdom, United States
Collaborators--

Timeline

Phase 2Active
2021202220232024202520262027
First PostedSep 21, 2020
Enrollment StartSep 17, 2020
Primary CompletionNov 9, 2021
Study CompletionMay 28, 2027
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 5.8 years ago

Arms & Interventions

Part 3: Teclistamabexperimental

Participants will receive teclistamab subcutaneously (SC) at recommended Phase 2 dose (RP2D) in Cohort A and Cohort C.

Drug: Teclistamab

Interventions

Teclistamabdrug

Teclistamab will be administered SC.